Dr. John Cush RheumNow
2 years 7 months ago
Frensius-Kabi has announced that the FDA has approved the tocilizumab biosimilar, Tyenne (tocilizumab-aazg); the first TCZ biosimilar with both IV and subcutaneous formulations https://t.co/cdSVbuBzXf https://t.co/CUC5v0hSxr
A systematic review of pharmacological treatments for adult-onset Still disease (AOSD) supports the efficacy of tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK).
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week.
Dr. John Cush RheumNow
2 years 7 months ago
Fibroblast activation w/ inflammatory arthritis studied by PET to detect fibroblast activation protein (FAP), but decreases after TNF or 17A inhib. Fibroblasts switch from pathogenic (MMP3+/IL6+) to pro-resolving phenotype (CD200+DKK3+) https://t.co/K1xAMqPiuT https://t.co/07NNgW9Lpv
Dr. John Cush RheumNow
2 years 7 months ago
Review article on inclusion body myositis, a progressive, debilitating myopathy w/ onset > 50 yrs. IBM typically has asmmetric, painless, weakness & atrophy of finger flexors or quadriceps w/ dysphagia. Most are wheelchair bound w/in 13-15 years https://t.co/jybZzCDYk5 https://t.co/FyVA5hveZ4
The CDC has updated its Lyme disease surveillance report based on a new case definition. Compared to 2017–2019, the number of cases in 2022 rose by 69%.
Dr. John Cush RheumNow
2 years 7 months ago
ICYMI: Teaching and Academic Burnout
RheumNow recently highlighted a publication that reported about a third of physicians in academia intend to leave.
https://t.co/uSVVJ6zl73 https://t.co/6BWwd2btMf
Dr. John Cush RheumNow
2 years 7 months ago
Preoperative Delay & Education Benefits Arthroplasty Patients
A randomized study shows having patients waiting for knee arthroplasty undergo a preoperative program of weight loss, exercise, etc gave them modestly improved pain/function/quality of life.
https://t.co/RSFwhFKq8U https://t.co/xgyQ65mUAO
Dr. John Cush RheumNow
2 years 7 months ago
Stills Dz Rx w/ IL-1 or IL-6 inhib may mask Dx of MAS! Study of 162 systemic JIA & MAS (62 on biologics). Biologic Rx pts had lower Plt, Ferritin (1107 vs 2863(, CRP (15 vs 90), ESR, fever duration. 27% on IL1/IL6i did not meetMAS classification criteria https://t.co/RmAzxh459R https://t.co/SXroqNBLSZ
A Korean nationwide cohort study found that both seropositive and seronegative rheumatoid arthritis (RA) patients have a significantly higher risk of depression.
Depression is one of the most common comorbidities in rheumatic disease patients and it imparts a significant morbidity and mortality risk for those affected.
Dr. John Cush RheumNow
2 years 7 months ago
Can Mycophenolate be Stopped in Stable SLE?
https://t.co/cDmarnHjAN https://t.co/YgG1jbP4Pw
Dr. John Cush RheumNow
2 years 7 months ago
EMR study identified 3.5+ million pts w/ BMI >30 -- 23% had sleep apnea (OSA). OSA had >2 fold risk of gout (7.2% vs 2.8%)vs those without OSA (p<0.0001). The odds of having gout are 2.65 times higher(HR 2.39; (CI) 2.367-2.419, p<0.0001). https://t.co/GgWrAiFPds https://t.co/QuQUk7nwDK
While it is believed that autoimmunity follows autoantibody positivity, a Danish study shows the incidence of polyautoimmunity to be similar in rheumatoid arthritis (RA) patients who are either anticyclic citrullinated peptide antibody (ACPA)–positive or ACPA–negative.
Data was drawn from RA adults in the DANBIO rheumatology register. Polyautoimmunity included 21 nonrheumatic autoimmune diseases.
According to the National Health Interview Survey (NHIS), in 2022, the prevalence of diagnosed arthritis in adults was 18.9% (women 21.5%, more than men 16.1%). These numbers are down since the CDC's MMWR report of 2019–2021, where is was estimated 21.2% of U.S. adults (53.2 million) had "diagnosed arthritis".
Trends show:
